PF-03882845

Overview

PF-03882845 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 and Type 2 Diabetic Nephropathy.

PF-03882845 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 and Type 2 Diabetic Nephropathy.

No indication information available.

No associated conditions information available.

Title	Posted	Study ID	Phase	Status	Sponsor
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy	2011/12/08	NCT01488877	Phase 1	Terminated	Pfizer
A Study Of PF-03882845 Absorption In Healthy Volunteers Given Orally As Tablet Versus Suspension Formulations And Effect Of Food On Its Absorption	2011/06/06	NCT01366287	Phase 1	Completed	Pfizer
A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers	2011/03/15	NCT01314898	Phase 1	Completed	Pfizer
A Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-03882845 In Healthy Volunteers	2009/09/04	NCT00971802	Phase 1	Completed	Pfizer

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

No news found